Jonathan Trent, MD, PhD, provides insight on how the patient with gastrointestinal stromal tumor is found to have developed further disease progression based on imaging findings, and therefore, therapy was changed to regorafenib, the standard option for after progression on sunitinib.

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть